Improved Mental and Physical Condition is Directly Linked to Nutrition, Study Shows Medical Device Investing
U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® in Combination with CABOMETYX® in Advanced Renal Cell Carcinoma Biotech Investing
Merck Presents Three-Year Survival Data for KEYTRUDA® in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab in Combination With KEYTRUDA in Advanced Non?Small Cell Lung Cancer Pharmaceutical Investing
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Biotech Investing
European CHMP Adopts Positive Opinion for Kite's KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Biotech Investing
Health Canada Approves KEYTRUDA® as First-line Treatment for Patients with Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma Pharmaceutical Investing
FDA Approves Expanded Indication for Merck's KEYTRUDA® in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Pharmaceutical Investing
Gilead Sciences to Release Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 Biotech Investing
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for Immunomedics Tender Offer Biotech Investing
Numinus Appoints Multidisciplinary Global Leaders to its General Advisory Council Cannabis Investing News
